Ohio State University spinout Entrada Therapeutics has pocketed $116m in a series B round.
Entrada Therapeutics, a US-based drug delivery platform developer spun out of Ohio State University, secured $116m in its series B round today led by Wellington Management.
Roche Venture Fund and MRL Ventures Fund, respective vehicles for pharmaceutical firms Roche and Merck & Co, also took part in the round together with CureDuchenne Ventures, the investment arm of nonprofit CureDuchenne.
Redmile Group, TCG Crossover, Greenspring Associates, Point72, Moore Strategic Ventures, Qatar Investment Authority, Goldman Sachs, 5AM Ventures, MPM Capital,…
